# SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

> **NCT05436639** · PHASE2 · COMPLETED · sponsor: **Sparrow Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Autonomous Cortisol Secretion (ACS)
- ACTH-Independent Cushing Syndrome
- ACTH-Independent Adrenal Cushing Syndrome, Somatic

## Interventions

- **DRUG:** SPI-62 dose

## Key facts

- **NCT ID:** NCT05436639
- **Lead sponsor:** Sparrow Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-02-18
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05436639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05436639, "SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05436639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*